Back
Full-text
Journal article

New Developments in Peptide Receptor Radionuclide Therapy.

  • Nicolas GP University Hospital Basel, University of Basel, Switzerland.
  • Morgenstern A Directorate for Nuclear Safety and Security, Germany.
  • Schottelius M Technische Universität München, Germany.
  • Fani M University Hospital Basel, University of Basel, Switzerland.
  • 2018-12-22
Published in:
  • Journal of nuclear medicine : official publication, Society of Nuclear Medicine. - 2018
G-protein coupled receptors
Neuroendocrine
Peptides
Radionuclide Therapy
alpha radiation therapy
beta radiation therapy
targeted radionuclide therapy
theranostics
English Peptide Receptor Radionuclide Therapy (PRRT) is an established treatment for non-operable or metastatic neuroendocrine neoplasms that express highly and frequently somatostatin receptors. More generally, PRRT is an attractive therapy option for delivering cytotoxic radiation to tumor cells through specific binding of a radiolabeled peptide to a molecular target. The development of imaging companions gave rise to the concept of radiotheranostics, important for in vivo tumor detection, characterization, staging but also, and more importantly, for individual patient selection and treatment. The success of somatostatin receptor targeting paved the way for the clinical translation of other peptide-based radiopharmaceuticals targeting, e.g. the receptors Cholecystokinin 2, Gastrin Releasing Peptide (GRPR), Neurokinin-1 and C-X-C motif chemokine 4 (CXCR4). While historically the Auger emitter 111In and the high-energy β- emitter 90Y were used, the vast majority of PRRT are currently performed with the medium-energy β- emitter 177Lu, while α emitters are increasingly studied in various clinical applications.
Language
  • English
Open access status
bronze
Identifiers
Persistent URL
https://sonar.ch/global/documents/49796
Statistics
Document views: 36 File downloads:
  • Full-text: 0